Monday, November 03, 2025 4:08:11 PM
It is pretty much impossible, even with charts, to forecast hit pieces (2 major ones recently). Yahoo finance has AVXL as the 13th highest shorted stock. Think about that. You have been around stocks long enough to know that "news trumps charts". All of us here TA and FA are just doing the best we can when facing extreme negative manipulation. It is what it is. What has been applicable for over a decade? "Buy dips and sell rips." Just another one currently.
For the 30 days since Sept 15 shorts have increased their positions by 6%. They are all over AVXL to stop a short squeeze if approval comes or to start covering down here IMO. Will find answers one way or the other soon.
AI Overview
Anavex Life Sciences (AVXL) is one of the most heavily shorted stocks, with short interest representing approximately 32% to 34.8% of its public float as of the latest data from mid-October 2025. While it consistently ranks high, an exact overall market rank can fluctuate daily.
AVXL Short Interest Details (as of Oct 15, 2025)
Metric Value
Short Interest % of Float ~32.0% - 34.8%
Total Shares Short ~26.62 million
Days to Cover ~15.5 to 23.8 days
Change from Previous Month Increased by approximately 6%
Ranking Context
High Percentage: A short interest percentage above 10% is generally considered high, and anything over 20% is extremely high. AVXL's percentage puts it in a category with some of the most shorted stocks on major US exchanges.
Top 10/20 Range: While daily rankings change, stocks with this level of short interest are typically among the top 10 to 20 most shorted stocks by percentage of float nationally.
Industry Context: It ranks highly within the biotechnology and pharmaceutical sectors for short interest.
The high "days to cover" ratio indicates that it would take several days of average trading volume for all short sellers to exit their positions, which could lead to significant price volatility (a potential "short squeeze") if positive news were to emerge.
For the 30 days since Sept 15 shorts have increased their positions by 6%. They are all over AVXL to stop a short squeeze if approval comes or to start covering down here IMO. Will find answers one way or the other soon.
AI Overview
Anavex Life Sciences (AVXL) is one of the most heavily shorted stocks, with short interest representing approximately 32% to 34.8% of its public float as of the latest data from mid-October 2025. While it consistently ranks high, an exact overall market rank can fluctuate daily.
AVXL Short Interest Details (as of Oct 15, 2025)
Metric Value
Short Interest % of Float ~32.0% - 34.8%
Total Shares Short ~26.62 million
Days to Cover ~15.5 to 23.8 days
Change from Previous Month Increased by approximately 6%
Ranking Context
High Percentage: A short interest percentage above 10% is generally considered high, and anything over 20% is extremely high. AVXL's percentage puts it in a category with some of the most shorted stocks on major US exchanges.
Top 10/20 Range: While daily rankings change, stocks with this level of short interest are typically among the top 10 to 20 most shorted stocks by percentage of float nationally.
Industry Context: It ranks highly within the biotechnology and pharmaceutical sectors for short interest.
The high "days to cover" ratio indicates that it would take several days of average trading volume for all short sellers to exit their positions, which could lead to significant price volatility (a potential "short squeeze") if positive news were to emerge.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
